Amid congressional hearings over high prices, pharma blames middlemen

26 February 2019
drug_money_big

The leading trade group lobbying for the US pharma industry has released a new analysis pinning the blame for high drug prices on so-called middlemen in the healthcare sector.

The release of the report coincides with potentially negative media coverage, with congressional hearings taking place on Tuesday, in which chief executives from six of the world’s largest drugmakers face questions from senators over high prices.

The pharma industry has long blamed pharmacy benefit managers (PBM) and other intermediaries for high prices.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical